4502.T
Latest Trade
4,385.00JPYChange
-64.00(-1.44%)Volume
3,897,600Today's Range
-
4,441.0052 Week Range
-
4,822.00As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 4,449.00 |
|---|---|
Open | 4,440.00 |
Volume | 3,897,600 |
3M AVG Volume | 104.43 |
Today's High | 4,441.00 |
Today's Low | 4,376.00 |
52 Week High | 4,822.00 |
52 Week Low | 3,401.00 |
Shares Out (MIL) | 1,557.75 |
Market Cap (MIL) | 6,912,325.00 |
Forward P/E | -24.69 |
Dividend (Yield %) | 4.10 |
Takeda Canada Says TAKHZYRO Gets Positive Recommendation From CADTH's CDEC For Routine Prevention Of HAE Attacks
Finch Therapeutics & Takeda Expand Collaboration To Develop Microbiome Therapeutics
Takeda And MD Anderson Announce Collaboration
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Industry
Major Drugs
Executive Leadership
Masahiro Sakane
Independent Chairman of the Executive Board
Christophe Weber
President, Chief Executive Officer, Representative Director
Constantine Saroukos
Chief Financial Officer, Director
Masato Iwasaki
President of Japan Pharma Business Unit, President of Subsidiary, Director
Andrew S. Plump
President of Research & Development, Director
Price To Earnings (TTM) | 136.60 |
|---|---|
Price To Sales (TTM) | 2.40 |
Price To Book (MRQ) | 1.40 |
Price To Cash Flow (TTM) | 12.52 |
Total Debt To Equity (MRQ) | 103.27 |
LT Debt To Equity (MRQ) | 99.74 |
Return on Investment (TTM) | 0.22 |
Return on Equity (TTM) | 0.18 |
An additional six months of data from a late-stage trial of Takeda Pharmaceutical Co's experimental dengue vaccine again showed it failed to protect against one of the four types of the virus in an important patient group, researchers said on Saturday.
Germany's Stada <STAGn.D> on Tuesday agreed to purchase over-the-counter and prescription drugs units from Japan's largest drugmaker Takeda <4502.T> for $660 million (£512 million), part of two deals that boost its Russian and Eastern European footprint.
Takeda Pharmaceutical Co Ltd said on Tuesday it would sell some of its over-the-counter and prescription drugs to Germany's STADA Arzneimittel AG for a total value of $660 million.
Takeda Pharmaceutical <4502.T> trimmed its full-year loss forecast on strong sales of its core drugs and progress in its consolidation with Shire Plc.
Takeda Pharmaceutical Co Ltd said on Thursday its half year profit fell by 70%, and the company trimmed its estimate for a full-year loss.
Japan's Takeda Pharmaceutical Co Ltd <4502.T> said on Tuesday it will sell a portfolio of over-the-counter (OTC) and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino for more than $200 million.
Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it will sell a portfolio of over-the-counter (OTC) and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino for more than $200 million.
German dialysis specialist Fresenius Medical Care <FMEG.DE> has hired Helen Giza from Japan's Takeda Pharmaceutical <4502.T> as its new finance chief, replacing Mike Brosnan.
Japan's Takeda Pharmaceutical Co <4502.T> has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters.
The Japanese Olympic Committee (JOC) picked former Olympic judo champion Yasuhiro Yamashita as its new chief after the resignation of Tsunekazu Takeda, who is being investigated for suspected corruption related to the Tokyo 2020 bid.
Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals.
Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.
Takeda Pharmaceutical Co forecast an unexpected operating loss for the current year due to costs associated with the $59 billion purchase of Shire Plc, providing the first set of financial results of the combined firm.
Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar Shire deal.
Novartis is buying dry-eye drug Xiidra from Takeda Pharmaceutical Co for up to $5.3 billion as the Swiss drugmaker refreshes its ophthalmic medicines portfolio with a potential blockbuster.
Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for an upfront payment of $3.4 billion to expand its portfolio of eye care medicines.
* TAKEDA SIMPLIFIES PORTFOLIO AND ACCELERATES DELEVERAGING THROUGH TWO DIVESTITURES
* REG-NOVARTIS TO ACQUIRE XIIDRA®, EXPANDING FRONT-OF-EYE PORTFOLIO AND STRENGTHENING LEADERSHIP IN EYE CARE
Japan's Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America, three people with knowledge of the matter said.
Japan's Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America, three people with knowledge of the matter said.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.